Ovarian large cell neuroendocrine carcinoma

Tsuji, Takahiro; Togami, Shinichi; Shintomo, Nao; Fukamachi, Nobuyuki; Douchi, Tsutomu; Taguchi, Shuuhei

doi:10.1111/j.1447-0756.2008.00916.x

Cited by 18 publications

(20 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This extremely rare clinical presentation of a huge mass arising from an anatomically normal ovary confirmed laparoscopically, 9 months back was reiterating the fact that this tumour was rapidly growing. Some authors have similar opinion [1][2][3][4][5][6].…”

Section: Discussionmentioning

confidence: 82%

Neuroendocrine Tumors of the Female Reproductive Tract: A Literature Review

Chun¹

2015

J Pathol Transl Med

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma (LCNEC) of the ovary is a rare tumor and is now included in the World Health Organization tumor classification. Its prognosis is generally very poor even when the diagnosis is made at an early stage. We report a case of pure large cell neuroendocrine tumour of ovary, appearing 9 months following laparoscopic type I hysterectomy, bilateral pelvic lymph node dissection with ovarian preservation of anatomically normal looking ovaries performed for a cervical biopsy diagnosis of cervical intraepithelial neoplasia grade III with foci of invasion. The rarity lies in the rapid onset (9 months) of a large tumor following conservation of an anatomically normal ovaries. Surgical debulking and five cycles of chemotherapy (Etoposide and Cisplatin) were administered to the woman. She is on followup with no clinical or radiological evidence of disease recurrence for 6 months.

show abstract

Section: Discussionmentioning

confidence: 82%

Neuroendocrine Tumors of the Female Reproductive Tract: A Literature Review

Chun¹

2015

J Pathol Transl Med

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry revealed that the cells of the poorly differentiated component were diffusely positive for CD56, chromogranin A, synaptophysin and NSE. Taken together, the tumor fulfilled the histopathological criteria for a neuroendocrine carcinoma …”

Section: Discussionmentioning

confidence: 86%

“…However, there exist no generally accepted criteria for neuroendocrine tumor differentiation, which usually depends on a combination of typical structural, immunohistochemical and ultrastructural findings. World Health Organization (WHO) criteria describe that LCNEC of the lung is characterized by positive immunostaining for chromogranin A, synaptophysin or CD56 (N‐CAM) and at least one of them is enough if the staining is clear cut . LCNEC of the ovary is very rare and only 35 cases have been reported previously worldwide .…”

Section: Introductionmentioning

confidence: 99%

“…World Health Organization (WHO) criteria describe that LCNEC of the lung is characterized by positive immunostaining for chromogranin A, synaptophysin or CD56 (N-CAM) and at least one of them is enough if the staining is clear cut. 2 LCNEC of the ovary is very rare and only 35 cases have been reported previously worldwide. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] Its prognosis is generally very poor, even when the diagnosis is made at an early stage.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: Case report and review of published works

Asada

Kawana

Teshima³

et al. 2013

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma (LCNEC) is well-reported to result in unfavorable prognoses in many organ cancers while being rarely reported in gynecologic cancer, especially ovarian and endometrial cancers. Here we report a case of ovarian cancer with LCNEC which spread to distant organs within 1 year of primary surgery despite the fact that the post-surgical stage was Ia. The case received platinum-based chemotherapy as an adjuvant therapy after her curative surgery. However, LCNEC in the case was resistant to the chemotherapy. In our review of published works, ovarian cancer cases with LCNEC show poor prognoses regardless of adjuvant chemotherapy following complete resection. Median overall survival was 10 months in stage I cases. Development of chemotherapy sensitive for LCNEC is needed.

show abstract

“…The optimal chemotherapy regimen for LCNECs has not been established. Regimens used for LCNECs are cisplatinum-based chemotherapy or paclitaxel-carboplatin based chemotherapy [9,10]. Patients usually follow an extremely lethal outcome.…”

Section: Discussionmentioning

confidence: 99%

A case of ovarian large cell neuroendocrine carcinoma

Lee

et al. 2012

Korean J Obstet Gynecol

View full text Add to dashboard Cite

Large cell neuroendocrine carcinoma (LCNEC) of the ovary is a rare entity and is frequently associated with ovarian surface epithelial tumors. Since Collins et al. described the fi rst case of mixed neuroendocrine and mucinous carcinoma, a few more cases of primary ovarian LCNECs have been reported. The prognosis of LCNECs is generally very poor even when the diagnosis is made at an early stage. A 40-year-old woman presented with a pelvic mass measuring 30 cm in diameter. She underwent an exploratory laparotomy for resection of the pelvic mass and staging if needed. After the operation, she was diagnosed of stage Ia LCNEC associated with mucinous tumor (including benign, borderline, malignant tumor) of left ovary. The patient received six cycles of paclitaxel-carboplatin chemotherapy postoperatively. There have been no signs of local tumor recurrence or metastasis at followup examinations during the fi rst 8 months after the operation.Keywords: Carcinoma; Neuroendocrine; Large cell type; Ovary CASE REPORT Received: 2011. 8.16. Accepted: 2011 Neuroendocrine differentiation may be expressed in a variety of ovarian tumors including surface epithelial tumor, Sertoli-Leydig cell tumors, teratomas, carcinoid tumor, small cell carcinoma of pulmonary type, small cell carcinoma of hypercalcemic type, and non-small cell undifferentiated carcinoma of neuroendocrine type [1]. According to the definition of World Health Organization, primary ovarian large cell neuroendocrine carcinoma (LCNEC) is synonymous with 'undifferentiated carcinoma of non-small cell neuroendocrine type' [2]. Its prognosis is generally very poor even when the diagnosis is made at an early stage. Most patients have died of disseminated disease within one year after primary operation even extensive chemotherapy. And the longest recorded survival is 68 months [3]. Due to the rarity of LCNECs, a general consensus for optimal treatment has yet to emerge. We report a primary ovarian large cell neuroendocrine carcinoma associated with ovarian epithelial micinous tumor (including benign, borderling, malignant tumor). Case ReportA 40-year-old multiparous woman was referred for abdominal distension sustained for 3 months. Physical examination revealed a fi rm, round, regular mass in the abdomen. A computed tomography (CT) scan of her abdomen and pelvis showed about 30 cm sized multilocular cystic tumor with enhancing portions in left ovary (Fig.1). There was no retroperitoneal lymphadenopathy or peritoneal deposits and no evidence of metastatic disease on the CT scan. At the time of admission, her vital signs were all within normal range and her general condition was good. Her hemoglobin level, red cell volume, leukocyte and platelet count were all normal level. Other urinalysis and blood chemistry results were within normal

show abstract

Ovarian large cell neuroendocrine carcinoma

Cited by 18 publications

References 7 publications

Neuroendocrine Tumors of the Female Reproductive Tract: A Literature Review

Neuroendocrine Tumors of the Female Reproductive Tract: A Literature Review

Poor prognosis of ovarian cancer with large cell neuroendocrine carcinoma: Case report and review of published works

A case of ovarian large cell neuroendocrine carcinoma

Contact Info

Product

Resources

About